Skip to content
DataLookout
Menu

WARRIORNCT03417388

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

StatusActive, Not Recruiting
PhasePhase 4
Primary completion

At risk: Primary completion moved at least 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 49 versions: 42 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 31, 2024 to Feb 15, 2025
  2. Notable Eligibility criteria expanded, about 15 words Show 6 more changesShow less
    • Primary completion date changed from estimate of Sep 14, 2026 to May 31, 2024
    • Study completion pushed from Sep 14, 2026 to Apr 16, 2027
    • Secondary endpoints: details revised at 4 of 12 entries
    • Study description revised
    • Site details revised at 1 of 81 sites
    • Publications: details revised at 4 of 4 entries
  3. Notable Sponsor changed: University of Florida to Cedars-Sinai Medical Center
    • Site details revised at 1 of 81 sites
    • Collaborators: 1 to 2
    v47
  4. Notable Primary and study completion dates pushed to Sep 14, 2026
    • Trial status: Completed to Active, Not Recruiting
    v46
  5. Minor Trial status: Active, Not Recruiting to Completedv45
Show 36 earlier versionsHide 36 earlier versions
  1. Notable Primary endpoints: 5 to 1v44 Show 4 more changesShow less
    • Primary completion date changed from estimate of Feb 28, 2025 to Jan 3, 2025
    • Study completion date: Sep 30, 2025 to Sep 14, 2025
    • Interventions: ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), Quality of… to ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin 81 enteric coated tablet daily (Drug), High dose potent statin (Drug), Lifestyle…
    • Secondary endpoints expanded, about 69 words
  2. Minor Primary completion date: Sep 30, 2024 to Feb 28, 2025
    • Study completion date: Dec 30, 2024 to Sep 30, 2025
    v43
  3. Notable Primary completion date: Sep 30, 2023 to Sep 30, 2024v41 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 4422 to confirmed 2476
    • Study sites: 83 to 81
    • Study completion date: Dec 30, 2023 to Dec 30, 2024
  4. Minor Study sites: 84 to 83v40
  5. Minor Study sites: 68 to 84v39
  6. Notable Primary completion date: Dec 30, 2021 to Sep 30, 2023
    • Study completion date: Dec 30, 2022 to Dec 30, 2023
    • Study description revised
    v38
  7. Minor Study sites: 66 to 68v37
  8. Minor Study sites: 53 to 66v36
  9. Notable Eligibility criteria expanded, about 5 words
    • Study sites: 49 to 53
    v35
  10. Minor Study sites: 46 to 49v34
  11. Minor Study sites: 45 to 46v33
  12. Minor Site details revised at 2 of 45 sitesv32
  13. Minor Study sites: 44 to 45v31
  14. Minor Study sites: 41 to 44v30
  15. Minor Study sites: 30 to 41v29
  16. Notable Eligibility criteria shortened, about 12 words
    • Study sites: 29 to 30
    v28
  17. Minor Study sites: 28 to 29v27
  18. Notable Eligibility criteria revisedv25
  19. Minor Study sites: 27 to 28v24
  20. Notable Eligibility criteria revised
    • Study sites: 25 to 27
    v23
  21. Notable Eligibility criteria expanded, about 52 wordsv21
  22. Minor Study sites revised (25)v20
  23. Minor Study sites: 24 to 25v18
  24. Notable Enrollment target: 550 to 4422
    • Study sites: 23 to 24
    v17
  25. Notable Eligibility criteria expanded, about 1 wordv16
  26. Minor Study sites: 21 to 23v15
  27. Minor Study sites: 20 to 21v14
  28. Minor Study sites: 21 to 20
    • Interventions: ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), PCSK9… to ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), Quality of…
    • Study description shortened, about 19 words
    v13
  29. Minor Study sites: 20 to 21v12
  30. Minor Study sites: 17 to 20v10
  31. Minor Study sites: 15 to 17v9
  32. Minor Study sites: 12 to 15v8
  33. Notable Enrollment target: 4422 to 550
    • Interventions: ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), Evolocumab (Drug), High dose potent statin (Drug), Lifestyle Counseling… to ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), PCSK9…
    v5
  34. Minor Study sites: 11 to 12v4
  35. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Feb 2, 2018 to Feb 9, 2018
    • Study description revised
    • Site details revised at 11 of 11 sites
    • Study title shortened, about 1 word
  36. Minor Study description expanded, about 1 wordv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The primary outcome is MACE, defined as first occurrence of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for angina or HF.
Timeframe: Within 5 years

Secondary (12)

Components of MACE
Composite hierarchical MACE endpoint
Seattle Angina Questionnaire (SAQ).
EQ-5D-3L
Duke Activity Status Inventory (DASI)
Show 7 moreShow less
Modified Morisky Medicine Scale Take your medication
PACE (Programs of All-Inclusive Care for the Elderly).
PCL-5 (Screening for PTSD).
Health care utilization and cost effectiveness
GAD 7
PHQ 8
MACE and Quality of Life outcomes will also be stratified by enrollment assessment of non-obstructive CAD using noninvasive CCTA vs invasive coronary angiography

Arms and interventions

Intensive Medical Treatment (IMT)Experimental

The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and "face-time" with site staff to reduce bias.

Usual Care (UC)Active comparator

The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and "face-time" with site staff to reduce bias.

Drugs: High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily

Behavioral: Lifestyle Counseling, Quality of Life Questionnaires

Sites

81 sites in 2 countries

United States 80, Puerto Rico 1